EFFICACY OF NON-PHARMACOLOGICAL AND PHARMACOLOGICAL TREATMENT OF OVERACTIVE BLADDER: A RANDOMIZED TRIAL
DOI:
https://doi.org/10.34921/amj.2023.4.007Keywords:
urinary incontinence, overactive bladder, pharmacological treatment, pelvic floor muscle stimulation, fractional CO2 laserAbstract
The article presents information on a scientific study conducted to assess the efficacy of pelvic floor muscle stimulation (PFMS) with biofeedback and fractional CO2 laser, either seperately or in combination with an antimuscarinic and selective β3-agonist in the treatment of patients with overactive bladder (OAB). 105 female patients with OAB were included in a prospective randomized trial and divided into three equal groups: Group 1, patients receiving a PFMS with a fractional CO2 laser (non-pharmacological treatment group, Non-Pharm); Group 2, patients receiving a combination of PFMS with fractional CO2 laser and pharmacological agents (Mix), Group 3, patients receiving a pharmacological agent (Pharm). PFMS treatment continued for 10 days, fractional CO2 laser was used twice, and pharmacological agents were prescribed for three months. The time points: before treatment, 3 and 6 months after treatment. All parameters of the bladder diary improved significantly in all groups after 3 months (p<0.05), but the beneficial effect persisted up to 6 months in the Mix group. There was a higher improvement in frequency of urination per day and night, no urinary urgency, and no postmicturition urinary residual in Mix and Pharm groups than in Non-Pharm after 3 months. There was a higher improvement in urine flow rate in Non-Pharm and Mix groups after 3 and 6 months. The frequency of urination and urine flow rate before treatment were predictors of favorable outcome. The combination of an antimuscarinic and a selective β3 agonist with biofeedback PFMS and fractional CO2 laser is superior to either method alone in patients with OAB.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Azerbaijan Medical Journal
![Creative Commons License](http://i.creativecommons.org/l/by/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution 4.0 International License.